^
1d
Trial initiation date
|
gemcitabine • Copiktra (duvelisib) • bendamustine
1d
New P2 trial
|
Poteligeo (mogamulizumab-kpkc)
1d
CD70-CAR-NK Cell Therapy for T Cell Lymphoma and Acute Myeloid Leukemia (clinicaltrials.gov)
P1, N=25, Not yet recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University
New P1 trial
3d
Rapidly enlarging primary cutaneous anaplastic large T-cell lymphoma of the eyelid: A case report. (PubMed, J Pak Med Assoc)
Computed tomography (CT) scanning of the orbit revealed no extension, and positron emission tomography-computed tomography (PET-CT) showed no systemic involvement. The patient underwent surgical excision without adjuvant chemoradiation and has remained in clinical remission for five months.
Journal
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 positive
5d
Quinoline- and coumarin-based ligands and their rhenium(I) tricarbonyl complexes: synthesis, spectral characterization and antiproliferative activity on T-cell lymphoma. (PubMed, J Inorg Biochem)
These rhenium(I) tricarbonyl complexes also slightly increased ROS production and significantly decreased the mitochondrial membrane potential by 50 % (5eRe) and 45 % (6dRe) compared to untreated cells and cells treated with 5e and 6d. These results suggest that the cytotoxic effects of these compounds are mediated by their effects on mitochondrial membrane potential and the subsequent increase in ROS production.
Journal
|
GLI2 (GLI Family Zinc Finger 2)
5d
Anaplastic Large B-Cell Lymphoma: Cutaneous Presentations. (PubMed, Cureus)
This case underscores the importance of early biopsy and molecular testing when standard treatments fail. Early recognition and routine examinations, including lymph node assessments and skin biopsies, are critical for improving patient outcomes, as timely diagnosis leads to more effective treatment options and potential remission.
Journal
|
ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 expression • ALK negative
|
Adcetris (brentuximab vedotin)
5d
Characteristics and therapeutic outcomes of subcutaneous panniculitis-like T-cell lymphoma with and without germline HAVCR2 mutations in Thai children and adolescents. (PubMed, Orphanet J Rare Dis)
Pediatric SPTCL in Thailand frequently involves germline HAVCR2 mutations and/or HLH/HLH-like systemic illnesses. With comparable response and modest therapy-related toxicity, IST-based regimens may alternatively be considered as first-line treatment for pediatric SPTCL.
Journal
|
HAVCR2 (Hepatitis A Virus Cellular Receptor 2)
6d
Epstein-Barr Virus-Driven T-Cell Lymphoma with Haemophagocytic Lymphohistiocytosis: A Life-Threatening Disorder Extending Beyond Childhood. (PubMed, Eur J Case Rep Intern Med)
EBV-associated T-cell lymphoma with haemophagocytic lymphohistiocytosis can affect not only children but also adolescents and young adults, highlighting the need for awareness of the high fatality risk.Early recognition of EBV-associated haemophagocytic lymphohistiocytosis (EBV-HLH) is crucial; when a patient presents with fever, pancytopaenia and hepatosplenomegaly.Future prospective studies are warranted to determine the treatment strategy and the optimal patient population that requires early bone marrow transplantation when initial treatment is inadequate.
Journal
|
CD8 (cluster of differentiation 8)
|
ifosfamide • etoposide IV • methotrexate • dexamethasone
6d
Cutaneous T-cell lymphomas (PubMed, Bull Cancer)
Thanks to international cooperative groups, treatment of mycosis fungoides, CD30+ lymphoproliferations and erythrodermic lymphomas is now well established which is not the case for the other entities. Treatments may be classified in five categories: skin directed therapies, systemic non-chemotherapeutic treatments, immunomodulators, targeted immunotherapies and chemotherapies.
Review • Journal
|
CD8 (cluster of differentiation 8) • TNFRSF8 (TNF Receptor Superfamily Member 8)
7d
Hypopigmented mycosis fungoide. Case report (PubMed, Rev Med Inst Mex Seguro Soc)
It was administered treatment based on prednisone and phototherapy with a good response. This case makes possible an outlook of the demographic data of HMF, and it allows this entity to be taken into consideration for possible differential diagnoses that are not contemplated due to the limited dissemination of knowledge about this disease. It is important to emphasize the knowledge of HMF since early diagnosis and timely treatment will improve the prognosis in our patients and prevent them from being treated incorrectly.
Journal
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • CD5 (CD5 Molecule)
|
prednisone
7d
A Phase 2 study of acimtamig (AFM13) in patients with CD30-positive, relapsed or refractory peripheral T-cell lymphomas. (PubMed, Clin Cancer Res)
The promising clinical efficacy observed warrants further investigation, and development of acimtamig for patients with R/R CD30+ lymphomas continues in combination with allogeneic natural killer cells.
P2 data • Journal
|
TNFRSF8 (TNF Receptor Superfamily Member 8) • FCGR3A (Fc Fragment Of IgG Receptor IIIa)
|
TNFRSF8 positive • TNFRSF8 expression
|
Adcetris (brentuximab vedotin) • acimtamig (AFM13)
8d
Trial completion
|
CD7 (CD7 Molecule)
|
cyclophosphamide • autologous CD7-CAR T cells
9d
IDH1/2 Mutations in Lung Cancer: A Closer Look at Their Incidence, Origin, and Clinical Characteristics (AMP 2024)
IDH1/2 mutations are identified in a small subset of NSCLCs. Our findings suggest that >25% of these mutations are hematopoietic in origin with important implications for diagnosis and management of these patients. Among those with mutations arising from the lung neoplasm, IDH1/2 mutations were primarily seen in conjunction with another driver and were subclonal in nature, suggesting patterns of clonal heterogeneity and evolution.
Clinical • Tumor mutational burden
|
EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TMB (Tumor Mutational Burden) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
|
KRAS mutation • BRAF mutation • IDH wild-type • IDH1 R132 • IDH2 R140Q • IDH1 R132L • IDH2 R140 • IDH2 R172
|
MSK-IMPACT
9d
Demethylating Agents Combined with Venetoclax for High-risk T-Cell Lymphoma/leukemia Post-Transplant Relapse Prevention (clinicaltrials.gov)
P2, N=59, Recruiting, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
New P2 trial • Post-transplantation
|
Venclexta (venetoclax) • azacitidine • decitabine
9d
Sincerely20: Sintilimab Combined With Chidamide in Treating Peripheral T Cell Lymphoma (clinicaltrials.gov)
P2, N=51, Recruiting, Fudan University | Trial completion date: Sep 2025 --> Dec 2026 | Trial primary completion date: Dec 2023 --> Dec 2026
Trial completion date • Trial primary completion date • IO biomarker • Epigenetic controller
|
PD-L1 expression
|
Tyvyt (sintilimab) • Epidaza (chidamide)
13d
TELLOMAK: IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma (clinicaltrials.gov)
P2, N=170, Active, not recruiting, Innate Pharma | Trial completion date: Oct 2024 --> Jan 2026
Trial completion date • Combination therapy • Metastases
|
KIR3DL2 (Killer Cell Immunoglobulin Like Receptor Three Ig Domains And Long Cytoplasmic Tail 2)
|
lacutamab (IPH4102)
15d
Sonodynamic Cancer Therapy by Mn(I)-tricarbonyl complexes via Ultrasound-triggered CO release and ROS generation. (PubMed, Chemistry)
This is the first report of Mn(I)-tricarbonyl-based sonosensitizers for cancer SDT. Overall, this study, for the first time, establishes the effectiveness of 3d metal carbonyls in SDT.
Journal
|
CASP3 (Caspase 3)
15d
Feasibility of Longitudinal Circulating Tumor DNA (ctDNA) Assessment in Patients with Peripheral and Cutaneous T-Cell Lymphomas (ASH 2024)
In 5 patients with PTCL, ctDNA negativity showed 100% concordance with negative PET-CT results. Our results, albeit with small numbers, suggest that ctDNA is strongly associated with clinical outcomes in patients with PTCL; ctDNA may serve as a useful tool to monitor and prognosticate patients with PTCL when validated in a large cohort of patients.
Clinical • Circulating tumor DNA
|
ALK (Anaplastic lymphoma kinase)
|
Signatera™
17d
A Study to Evaluate Activity, Safety and Tolerability of ZX-101A in Relapsed/Refractory Hematological Malignancies (clinicaltrials.gov)
P1/2, N=40, Completed, Nanjing Zenshine Pharmaceuticals | Recruiting --> Completed | N=70 --> 40
Trial completion • Enrollment change
|
ZX-101A
17d
Tumour assessment of ROR1 levels in various adult leukaemia and lymphoma types. (PubMed, PLoS One)
Finally, all acute myeloid leukaemia (n = 52) and most T-cell non-Hodgkin lymphoma (n = 31/32) tested samples were negative for ROR1 via IHC. In conclusion, ROR1 shows a heterogeneous tumour cell expression profile across multiple leukaemias and lymphomas, making it a tumour target that would require different patient selection strategies to develop novel therapeutic modalities.
Journal
|
ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1)
17d
Refining Diagnostic Subtypes of Peripheral T-cell Lymphoma Using a Multiparameter Approach. (PubMed, Mod Pathol)
The PTCL-TFH cases correlated with an angioimmunoblastic T-cell lymphoma (AITL) gene signature, had more EBER-positive cells than the PTCL-GATA3 and PTCL-TBX21 cases, and a subset had some morphologic features of AITL (p < 0.01). This study highlights the unique morphologic and phenotypic variations within the newly-identified PTCL subtypes and should enable more precise diagnosis and tailored therapeutic strategies in the future.
Journal • IO biomarker
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CD8 (cluster of differentiation 8) • TNFRSF8 (TNF Receptor Superfamily Member 8) • CD4 (CD4 Molecule) • ICOS (Inducible T Cell Costimulator) • TBX21 (T-Box Transcription Factor 21) • GATA3 (GATA binding protein 3)
|
TNFRSF8 expression • MYC expression
17d
Enrollment closed
|
CD8 (cluster of differentiation 8) • B3GAT1 (Beta-1,3-Glucuronyltransferase 1)
|
KT-333
17d
New trial
|
Epidaza (chidamide) • Folotyn (pralatrexate)
18d
Hematopoietic Neoplasms of the Sinonasal Tract. (PubMed, Surg Pathol Clin)
Hematologic malignancies are one of the more common neoplasms to occur in the sinonasal tract and include a wide range of entities, including mature and immature B cell and T cell neoplasms as well as plasma cell dyscrasias and histiocytic disorders. CD45 expression can be helpful in identifying many, but not all, hematopoietic neoplasms in the sinonasal tract, and more extensive immunophenotyping, including EBV in situ hybridization, as well as correlation with genetic results and clinical features may be required for diagnosis.
Review • Journal
|
PTPRC (Protein Tyrosine Phosphatase Receptor Type C)
|
PTPRC expression
19d
Valemetostat monotherapy in patients with relapsed or refractory non-Hodgkin lymphoma: a first-in-human, multicentre, open-label, single-arm, phase 1 study. (PubMed, Lancet Oncol)
The safety profile of valemetostat monotherapy was acceptable in these patients with relapsed or refractory non-Hodgkin lymphoma. Favourable clinical activity was observed. These findings support a new indication for valemetostat in this setting.
P1 data • Journal
|
EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit)
|
Ezharmia (valemetostat)
19d
Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 study. (PubMed, Lancet Oncol)
These data show that treatment with valemetostat leads to durable responses in patients with relapsed or refractory peripheral T-cell lymphoma, with a manageable safety profile.
P2 data • Journal
|
EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit)
|
Ezharmia (valemetostat)
21d
Journal
|
CD20 (Membrane Spanning 4-Domains A1)
|
CD20 expression
21d
OSU-17204: Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma (clinicaltrials.gov)
P2, N=26, Active, not recruiting, John Reneau | Trial completion date: Apr 2024 --> May 2025 | Trial primary completion date: Apr 2024 --> May 2025
Trial completion date • Trial primary completion date
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 positive
|
lenalidomide • Adcetris (brentuximab vedotin)
21d
GATA3 Immunohistochemical Staining in Classical Hodgkin Lymphoma and its Diagnostic Utility in Differential Diagnosis. (PubMed, Turk J Haematol)
GATA3 is a useful marker for differentiating CHL from B-cell non-Hodgkin lymphomas but its efficiency is limited in ALK (-) ALCL and mediastinal grey zone lymphomas. Due to the heterogeneous reaction diagnostic value is limited in core needle biopsies.
Journal
|
ALK (Anaplastic lymphoma kinase) • GATA3 (GATA binding protein 3)
21d
Recurrent somatic mutations of FAT family cadherins induce an aggressive phenotype and poor prognosis in anaplastic large cell lymphoma. (PubMed, Br J Cancer)
These findings provide novel insights into the molecular portrait of ALCL, that could help improve treatment strategies and the prognosis for ALCL patients.
Journal
|
ALK (Anaplastic lymphoma kinase) • RUNX1T1 (RUNX1 Partner Transcriptional Co-Repressor 1) • STAT3 (Signal Transducer And Activator Of Transcription 3) • YAP1 (Yes associated protein 1) • FAT4 (FAT Atypical Cadherin 4) • STAT1 (Signal Transducer And Activator Of Transcription 1)
|
ALK positive • ALK translocation • FANCA mutation • ALK negative
22d
Lymphoma in two wild tawny frogmouths (Podargus strigoides) in Victoria. (PubMed, Aust Vet J)
Cutaneous lymphoma should be considered as a potential differential diagnosis for severe feather loss in tawny frogmouths and other avian species, when other more common causes have been ruled out. Similarly, disseminated lymphoma is a differential diagnosis worthy of consideration in cases of systemic debilitation in tawny frogmouths.
Journal
|
PAX5 (Paired Box 5)
23d
Long-Term Remission With Allo-HSCT for t(1;8)(q25;p11) Translocation: A Rare Case Report and Literature Review. (PubMed, Transplant Proc)
we report the first case of EMS with t(1;8)(q25;p11) to have a favorable outcome after allo-HSCT. The encouraging results support the use of aggressive chemotherapy in conjunction with early allo-HSCT for EMS patients with t(1;8)(q25;p11).
Review • Journal
|
FGFR1 (Fibroblast growth factor receptor 1)
23d
Prognostic Utility of a Novel Prognostic Model Consisting of Age, CRP, Ki67, and POD24 in Patients with Angioimmunoblastic T-Cell Lymphoma. (PubMed, Indian J Hematol Blood Transfus)
The prognostic model established by them combined clinical features, and serological and pathological indicators and could effectively predict the prognosis of AITL patients. The online version contains supplementary material available at 10.1007/s12288-024-01767-1.
Journal
|
B2M (Beta-2-microglobulin) • CRP (C-reactive protein)
23d
Romidepsin Maintenance After Allogeneic Stem Cell Transplantation (clinicaltrials.gov)
P1, N=23, Active, not recruiting, Ohio State University Comprehensive Cancer Center | Recruiting --> Active, not recruiting | N=10 --> 23 | Trial completion date: Dec 2022 --> Dec 2024 | Trial primary completion date: Dec 2022 --> Dec 2024
Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
|
HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
|
Istodax (romidepsin) • fludarabine IV • busulfan
23d
Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas (clinicaltrials.gov)
P1/2, N=18, Completed, University of Colorado, Denver | Active, not recruiting --> Completed
Trial completion
|
ALK (Anaplastic lymphoma kinase)
|
ALK positive • ALK negative
|
Opdivo (nivolumab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisolone
24d
A Rare Coexistence of Turner Syndrome and Mycosis Fungoides: A Case Report. (PubMed, J Clin Res Pediatr Endocrinol)
This is the first reported case of MF in a child with TS. This case emphasises the importance of carefully evaluating skin lesions in patients with TS and suggests considering MF as a differential diagnosis.
Journal
|
CD4 (CD4 Molecule)
27d
Long-Term Survival in Canine Hepatosplenic T-Cell Lymphoma Treated with Toceranib Phosphate Following Splenectomy: A Case of Atypical Lymphoma. (PubMed, Vet Sci)
The dog stayed in remission after toceranib administration and survived for 460 days. Toceranib should be considered an effective treatment option for canine HSTCL.
Journal
|
GZMB (Granzyme B)
29d
Enrollment open
|
EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit)
|
RAS wild-type • EZH2 mutation • EZH2 wild-type
|
Tazverik (tazemetostat) • Beleodaq (belinostat)
30d
Modeling NK-cell lymphoma in mice reveals its cell-of-origin and microenvironmental changes and identifies therapeutic targets. (PubMed, Nat Commun)
Furthermore, targeting KLRG1 alone or combined with MYC inhibition using an eIF4 inhibitor is effective against NK-cell tumors. Therefore, our observations provide insights into the pathogenesis and highlight potential therapeutic targets, including CXCL16, KLRG1, and MYC, in ENKTCL, which can help improve its diagnostic and therapeutic strategies.
Preclinical • Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • IFNG (Interferon, gamma) • CXCR6 (C-X-C Motif Chemokine Receptor 6) • KLRG1 (Killer Cell Lectin Like Receptor G1)
|
MYC amplification • KLRG1 expression
1m
Journal
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
Adcetris (brentuximab vedotin)